scholarly article | Q13442814 |
P50 | author | Gwendolyn P Quinn | Q57056453 |
P2093 | author name string | Steven K Sutton | |
Teresita Muñoz-Antonia | |||
Vani N Simmons | |||
Matthew B Schabath | |||
Alberto Chiappori | |||
Iffat Alam | |||
P2860 | cites work | Biomarkers of Exposure among U.S. Adult Cigar Smokers: Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014) | Q64130688 |
National survey of perspectives of palliative radiation therapy: role, barriers, and needs | Q80257929 | ||
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018 | Q90101749 | ||
Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 | ||
Gene aberrations for precision medicine against lung adenocarcinoma | Q26749348 | ||
Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 | ||
Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas | Q33563803 | ||
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular | Q34159011 | ||
Getting physicians to respond: the impact of incentive type and timing on physician survey response rates | Q34554717 | ||
Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity | Q35016912 | ||
Lung cancer mutations and use of targeted agents in Hispanics | Q35636924 | ||
Why are response rates in clinician surveys declining? | Q35886455 | ||
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans | Q35915133 | ||
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). | Q36250691 | ||
Personalized medicine and access to health care: potential for inequitable access? | Q36543050 | ||
Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. | Q37684483 | ||
Physicians' attitudes about multiplex tumor genomic testing | Q37712065 | ||
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples | Q38061599 | ||
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology | Q40244899 | ||
Genotyping non-small cell lung cancer (NSCLC) in Latin America | Q43484361 | ||
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 | ||
Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013. | Q52648399 | ||
EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis | Q58741684 | ||
P433 | issue | 8 | |
P921 | main subject | biomarker | Q864574 |
P304 | page(s) | 33-40 | |
P577 | publication date | 2019-10-01 | |
P1476 | title | Use of biomarker testing in lung cancer among Puerto Rico and Florida Physicians: Results of a comparative study | |
P478 | volume | 5 |